Abstract:Adoptive cell immunotherapy, especially chimeric antigen receptor (CAR)-T-cells therapy, has made great progress in the clinical treatment of hematological malignancies. However, restricted by the complex tumor microenvironment, the potential efficiency of T-cell infiltration and activated immune cells are limited, thus failure prevented the progression of the solid tumor. Alternatively, tumor-associated macrophages (TAMs), one sustentacular and heterogeneous cellular population within the tumor microenvironment, are regarded as potential therapeutic targets. Recently, CARs have shown tremendous promise in treating malignancies by equipping macrophages. This novel therapeutic strategy circumvents the tumor microenvironment's limitations and provides a safer therapeutic approach. Meanwhile, nanobiomaterials as gene delivery carriers not only substantially reduce the treatment cost of this novel therapeutic strategy, but also set the foundation for in vivo CAR-M therapy. Here, we highlight the major strategies prepared for CAR-M, emphasizing the challenges and opportunities of these approaches. First, the common therapeutic strategies for macrophages are summarized in clinical and preclinical trials. Namely, TAM-targeted therapeutic strategies: 1) Inhibit monocyte or macrophage recruitment into tumors, 2) deplete TAMs, and 3) reprogramme TAMs to antitumor M1 phenotype. Second, the current development and progress of CAR-M therapy are reviewed, including the researchers' attempts in CAR structure design, cell origin, and gene delivery vectors, especially nanobiomaterials as an alternative to viral vectors, as well as some challenges faced by current CAR-M therapy are also summarized and discussed. Finally, the field of genetically engineered macrophages integration with nanotechnology for the future in oncology has been prospected.

Revolutionizing cancer treatment: the emerging potential and potential challenges of in vivo self-processed CAR cell therapy

Chimeric Antigen Receptor Natural Killer Cells: a Promising Antitumor Immunotherapy

Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

Fine-Tuning through Generations: Advances in Structure and Production of CAR-T Therapy

In vivo engineering chimeric antigen receptor immune cells with emerging nanotechnologies

Advanced Materials and Delivery Systems for Enhancement of Chimeric Antigen Receptor Cells

Direct in vivo CAR T cell engineering

In vivo gene editing and in situ generation of chimeric antigen receptor cells for next-generation cancer immunotherapy

Revolutionizing cancer treatment: an in-depth exploration of CAR-T cell therapies

A new era of cancer immunotherapy: combining revolutionary technologies for enhanced CAR-M therapy

Current progress in CAR-T cell therapy for tumor treatment

Recent Progress in Improving the Safety and Efficacy of Chimeric Antigen Receptor T Cell Therapy

CAR‐T cell therapy: A breakthrough in traditional cancer treatment strategies (Review)

Biomaterials promote in vivo generation and immunotherapy of CAR-T cells

CAR-T Cell Therapy in Cancer: Tribulations and Road Ahead

Recent advances in CAR-T cell engineering

CAR products from novel sources: a new avenue for the breakthrough in cancer immunotherapy

Emerging advances in nanobiomaterials-assisted chimeric antigen receptor (CAR)-macrophages for tumor immunotherapy

Recent Advancements in Biomaterials for CAR-T Immunotherapy

Chimeric antigen receptor-immune cells against solid tumors: Structures, mechanisms, recent advances, and future developments